BR0110150A - Method and composition for treating cancer by administering apoptosis-inducing chemotherapeutic agents - Google Patents

Method and composition for treating cancer by administering apoptosis-inducing chemotherapeutic agents

Info

Publication number
BR0110150A
BR0110150A BR0110150-1A BR0110150A BR0110150A BR 0110150 A BR0110150 A BR 0110150A BR 0110150 A BR0110150 A BR 0110150A BR 0110150 A BR0110150 A BR 0110150A
Authority
BR
Brazil
Prior art keywords
tumor
composition
chemotherapeutic agent
apoptosis
administering
Prior art date
Application number
BR0110150-1A
Other languages
Portuguese (pt)
Inventor
Moshe Flashner-Barak
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BR0110150A publication Critical patent/BR0110150A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"MéTODO E COMPOSIçãO PARA O TRATAMENTO DE CâNCER POR MEIO DA ADMINISTRAçãO DE AGENTES QUIMIOTERáPICOS INDUTORES DA APOPTOSE". A presente invenção provê um agente quimioterápico anti-tumor para um paciente portador de tumor, sendo que a composição compreende: microesferas que incorporam um agente quimioterápico anti-tumor; e uma solução de suspensão que cerca as microesferas. A presente invenção provê também um método para a administração de um agente quimioterápico anti-tumor a um paciente portador de tumor, compreendendo os passos de fornecer ao tumor o agente quimioterápico anti-tumor na forma de um reservatório quimioterápico; e liberar o agente quimioterápico anti-tumor do reservatório quimioterápico para um espaço intersticial do tumor numa quantidade terapeuticamente eficaz, em que o reservatório quimioterápico inclui microesferas que incorporam o agente quimioterápico anti-tumor e uma solução de suspensão que cerca as microesferas."METHOD AND COMPOSITION FOR THE TREATMENT OF CANCER THROUGH ADMINISTRATION OF APOPTOSIS CHEMOTHERAPIC AGENTS". The present invention provides an anti-tumor chemotherapeutic agent for a tumor-bearing patient, the composition comprising: microspheres incorporating an anti-tumor chemotherapeutic agent; and a suspension solution surrounding the microspheres. The present invention also provides a method for administering an anti-tumor chemotherapeutic agent to a tumor-bearing patient, comprising the steps of providing the tumor with the anti-tumor chemotherapeutic agent in the form of a chemotherapeutic reservoir; and releasing the anti-tumor chemotherapeutic agent from the chemotherapeutic reservoir to a tumor interstitial space in a therapeutically effective amount, wherein the chemotherapeutic reservoir includes microspheres incorporating the anti-tumor chemotherapeutic agent and a suspension solution surrounding the microspheres.

BR0110150-1A 2000-04-10 2001-04-10 Method and composition for treating cancer by administering apoptosis-inducing chemotherapeutic agents BR0110150A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19592000P 2000-04-10 2000-04-10
PCT/US2001/011688 WO2001076567A1 (en) 2000-04-10 2001-04-10 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents

Publications (1)

Publication Number Publication Date
BR0110150A true BR0110150A (en) 2004-04-27

Family

ID=22723363

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110150-1A BR0110150A (en) 2000-04-10 2001-04-10 Method and composition for treating cancer by administering apoptosis-inducing chemotherapeutic agents

Country Status (19)

Country Link
US (1) US20020041888A1 (en)
EP (1) EP1274404A1 (en)
JP (1) JP2004507451A (en)
KR (1) KR20030008368A (en)
CN (1) CN1438882A (en)
AU (1) AU2001253334A1 (en)
BR (1) BR0110150A (en)
CA (1) CA2406484A1 (en)
CZ (1) CZ20023333A3 (en)
EA (1) EA200201068A1 (en)
HU (1) HUP0302296A2 (en)
IL (1) IL152180A0 (en)
MX (1) MXPA02009984A (en)
NO (1) NO20024867L (en)
PL (1) PL366035A1 (en)
SK (1) SK14452002A3 (en)
WO (1) WO2001076567A1 (en)
YU (1) YU77002A (en)
ZA (1) ZA200208167B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20020680A1 (en) * 2002-03-29 2003-09-29 Acs Dobfar Spa IMPROVED ANTI-TUMOR COMPOSITION BASED ON PACLITAXEL AND METHOD FOR ITS OBTAINING
ITMI20020681A1 (en) * 2002-03-29 2003-09-29 Acs Dobfar Spa PROCEDURE FOR THE PRODUCTION OF PACLITAXEL AND ALBUMINA NANOPARTICLES
JP2005529127A (en) * 2002-04-26 2005-09-29 テバ ファーマシューティカル インダストリーズ リミティド Microparticle pharmaceutical composition for intratumoral delivery
CN1319525C (en) * 2004-09-16 2007-06-06 北京圣医耀科技发展有限责任公司 Taxinol-sodium alginate micro ball vascular embolism agent and its preparation
EP1807018A4 (en) * 2004-10-21 2012-07-04 Univ Iowa Res Found In situ controlled release drug delivery system
PT2301531T (en) 2005-02-18 2018-07-30 Abraxis Bioscience Llc Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
EP1896007B1 (en) 2005-05-04 2014-03-19 Medigene AG Method of administering a cationic liposomal preparation comprising paclitexel
AU2007228984B2 (en) 2006-03-22 2012-05-03 Syncore Biotechnology Co., Ltd Treatment of triple receptor negative breast cancer
SG10201906075VA (en) 2010-03-29 2019-08-27 Abraxis Bioscience Llc Methods of treating cancer
KR20130028727A (en) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 Methods of enhancing drug delivery and effectiveness of therapeutic agents
KR20190130050A (en) 2010-06-04 2019-11-20 아브락시스 바이오사이언스, 엘엘씨 Methods of treatment of pancreatic cancer
CN103429267B (en) * 2011-01-09 2016-05-04 Anp科技公司 Branched polymer aggregate of hydrophobic molecule induction and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4345588A (en) * 1979-04-23 1982-08-24 Northwestern University Method of delivering a therapeutic agent to a target capillary bed
US4492720A (en) * 1983-11-15 1985-01-08 Benjamin Mosier Method of preparing microspheres for intravascular delivery
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins

Also Published As

Publication number Publication date
NO20024867D0 (en) 2002-10-09
PL366035A1 (en) 2005-01-24
EP1274404A1 (en) 2003-01-15
YU77002A (en) 2005-09-19
CZ20023333A3 (en) 2003-06-18
CA2406484A1 (en) 2001-10-18
WO2001076567A1 (en) 2001-10-18
CN1438882A (en) 2003-08-27
SK14452002A3 (en) 2003-07-01
IL152180A0 (en) 2003-05-29
MXPA02009984A (en) 2004-09-10
AU2001253334A1 (en) 2001-10-23
EA200201068A1 (en) 2003-12-25
JP2004507451A (en) 2004-03-11
KR20030008368A (en) 2003-01-25
HUP0302296A2 (en) 2003-10-28
US20020041888A1 (en) 2002-04-11
ZA200208167B (en) 2004-02-10
NO20024867L (en) 2002-12-06

Similar Documents

Publication Publication Date Title
BR0110150A (en) Method and composition for treating cancer by administering apoptosis-inducing chemotherapeutic agents
BRPI0516177B8 (en) oligoribonucleotides, their use, use of a compound effective to inhibit human p53 and pharmaceutical composition containing them, as well as a method for decreasing p53 gene expression
Baczyk et al. 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma
BR0209147A (en) Combination therapy using anti-egfr antibodies and antihormonal agents
BR0108930A (en) Method of delivering an active agent to a cell type of interest, pharmaceutical composition, caspase-activated prodrug, kit, method of treating mammals, using a caspase conjugate and using a pro-agent
AR049985A1 (en) COMBINATION TREATMENT FOR NON-HEMATOLOGICAL MALIGNAL DISEASES
BR0115109A (en) Therapeutic agents and methods of their use for angiogenesis modulation
BR0012488A (en) Pharmaceutical composition, methods for improving the absorption rate of one or more than one pharmaceutically active agent in mammals, for improving the onset of the therapeutic benefit of one or more than one pharmaceutically active agent in mammals, for inhibiting gastroirritation in a mammal. , and for treating mammals requiring treatment provided by one or more than one pharmaceutically active agent, and, process for preparing a pharmaceutical composition.
BR0010648A (en) Use of biodegradable microspheres that release a radiosensitizing anti-cancer agent, process of preparing biodegradable microspheres, and suspension consisting of a sterile solution
MX9302038A (en) METHOD FOR THE TREATMENT OF CANCER BY A JOINT THERAPY WITH 2-HALOMETILIDENO DERIVATIVES AND A SPECIFIC PHASE M OR PHASE S ANTINEOPLASIC AGENT.
UY28213A1 (en) NEW CYANOPIRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS.
BR0209365A (en) Pharmaceutical uses of bisphosphonates
BRPI0508860A (en) passive targeting of cytotoxic agents
ECSP055911A (en) INHIBITING TRICYCLIC COMPOUNDS OF PROTEIN KINASE TO IMPROVE THE EFFECTIVENESS OF ANTINEOPLASSIC AGENTS AND RADIATION THERAPY
AR020051A1 (en) PROCEDURE FOR USE AND USE OF A COMBINATION OF AN ANTI-ERBB2 ANTIBODY AND A CHEMICAL THERAPEUTICAL AGENT OTHER THAN AN ANTHRACICLINE DERIVATIVE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR CANCER TREATMENT
BR9812122A (en) Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
BR0213906A (en) Methods for producing an anti-angiogenic and / or vascular permeability reducing effect in a warm-blooded animal, and for treating cancer in a warm-blooded animal, pharmaceutical composition, kit, and use of zd6474 or one thereof pharmaceutically acceptable salt and a taxane
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
BR0109672A (en) Use of zd6126 or a pharmaceutically acceptable salt thereof and one of: a plantin antitumor agent and a taxane, pharmaceutical composition, combination product, kit, and method for producing a vascularly damaging effect on a warm-blooded animal
BRPI0511800A (en) irinotecan treatment (cpt-11) and an egfr inhibitor
BR0207316A (en) Epothilone derivatives for the treatment of refractory tumors
EP2020237A3 (en) Ceramide and chemotherapeutic agents for inducing cell death
BR0109602A (en) Stavudine-containing controlled release globules
ITRM980303A1 (en) COMPOSITION CONTAINING IMMOBILIZED RADIOISOTOPES ON SOLID PARTICLES USEFUL IN PARTICULAR FOR CLINICAL LINEN IN PATHOLOGIES
BR0211855A (en) Drug and method for treating and improving restorative sleep quality

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19.08.2008.